PMID- 31200086
OWN - NLM
STAT- MEDLINE
DCOM- 20190722
LR  - 20190722
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 710
DP  - 2019 Aug 20
TI  - Evaluation of the epidemiological and prognosis significance of ESR2 rs3020450 
      polymorphism in ovarian cancer.
PG  - 316-323
LID - S0378-1119(19)30577-3 [pii]
LID - 10.1016/j.gene.2019.06.017 [doi]
AB  - AIM: To investigate the correlation between the polymorphism of estrogen receptor 
      beta gene (ESR2) rs3020450 and cancer susceptibility, and explore the 
      epidemiological significance and the effect of ESR2 expression levels on the 
      prognosis of ovarian cancer. METHODS: Based on meta-analysis the association 
      between ESR2 rs3020450 polymorphism and cancer susceptibility was estimated and a 
      case-control design was used to verify this result in ovarian cancer. The 
      epidemiological effect of ESR2 rs3020450 polymorphism was assessed by 
      attributable risk percentage (ARP) and population attributable risk percentage 
      (PARP). Kaplan Meier plotters were used to evaluate overall survival (OS) and 
      progression-free survival (PFS) in ovarian cancer patients and GEPIA for the 
      differential expression of ESR2 levels in ovarian cancer and adjacent normal 
      tissues. RESULTS: The pooled analysis indicated no significant correlation 
      between the ESR2 rs3020450 polymorphism and the cancer susceptibility. In the 
      stratified analysis by cancer types, significantly decreased risk was found in 
      ovarian cancer (AG vs GG: OR = 0.73, 95%CI: 0.53-0.97, P = 0.03). Unconditional 
      logistic regression results of case-control study in ovarian cancer observed 
      significant differences in all comparisons (AG vs GG: OR = 0.81, 95%CI: 
      0.62-0.98, P = 0.04; AA vs GG: OR = 0.63, 95%CI: 0.42-0.92, P = 0.01 and AG + AA 
      vs GG: OR = 0.73, 95%CI: 0.53-0.96, P < 0.001). Based on meta-analysis and 
      case-control pooled results, ARP and PARP were evaluated respectively in allele 
      (21.95% and7.97%), heterozygote (36.99% and 12.11%) and dominant model (36.84% 
      and 12.97%) of rs3020450 polymorphism in ovarian cancer. The expression levels of 
      ESR2 in normal tissues was significantly higher than that in cancer tissues (OV, 
      Median, 4.7:0.21), and significant correlations were observed between high ESR2 
      expression levels and long OS (HR = 0.80, 95%CI: 0.70-0.92, P = 0.002) and PFS 
      (HR = 0.767, 95%Cl: 0.67-0.88, P < 0.001). CONCLUSION: Our results indicated that 
      ESR2 rs3020450 polymorphism was associated with ovarian cancer risk from 
      epidemiological perspective, and high ESR2 expression levels was associated with 
      long survival in patients with ovarian cancer.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Feng, Yajing
AU  - Feng Y
AD  - College of Public Health, Zhengzhou University, Zhengzhou, Henan, China; 
      Department of Nosocomial Infection Management, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, Henan, China.
FAU - Peng, Zhen
AU  - Peng Z
AD  - Department of Infectious Disease, People's Hospital of Zhengzhou University, 
      Henan Provincial People's Hospital, Zhengzhou, China.
FAU - Liu, Weigang
AU  - Liu W
AD  - Medical Record Statistics Office, Affiliated Hospital of Hebei University of 
      Engineering, Handan, Hebei, China.
FAU - Yang, Zhongyu
AU  - Yang Z
AD  - The Ohio State University College of Art and Science, Columbus, OH, USA.
FAU - Shang, Jia
AU  - Shang J
AD  - Department of Infectious Disease, People's Hospital of Zhengzhou University, 
      Henan Provincial People's Hospital, Zhengzhou, China.
FAU - Cui, Liuxin
AU  - Cui L
AD  - College of Public Health, Zhengzhou University, Zhengzhou, Henan, China. 
      Electronic address: zzulxcui@126.com.
FAU - Duan, Fujiao
AU  - Duan F
AD  - College of Public Health, Zhengzhou University, Zhengzhou, Henan, China; Medical 
      Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 
      Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20190612
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (ESR2 protein, human)
RN  - 0 (Estrogen Receptor beta)
SB  - IM
MH  - Aged
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - *Down-Regulation
MH  - Estrogen Receptor beta/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Logistic Models
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Ovarian Neoplasms/*epidemiology/*genetics
MH  - *Polymorphism, Single Nucleotide
MH  - Prognosis
OTO - NOTNLM
OT  - ESR2
OT  - Epidemiological evaluation
OT  - Ovarian cancer
OT  - Polymorphism
OT  - Prognosis
EDAT- 2019/06/15 06:00
MHDA- 2019/07/23 06:00
CRDT- 2019/06/15 06:00
PHST- 2019/02/13 00:00 [received]
PHST- 2019/06/05 00:00 [revised]
PHST- 2019/06/10 00:00 [accepted]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2019/07/23 06:00 [medline]
PHST- 2019/06/15 06:00 [entrez]
AID - S0378-1119(19)30577-3 [pii]
AID - 10.1016/j.gene.2019.06.017 [doi]
PST - ppublish
SO  - Gene. 2019 Aug 20;710:316-323. doi: 10.1016/j.gene.2019.06.017. Epub 2019 Jun 12.